Wells Fargo’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Wells Fargo’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-151	Closed	-$273	–	7749
2023 Q2	$273	Sell	151 -6,011	-98%	-$11K	﹤0.01%	6614
2023 Q1	$8.13K	Buy	6,162 +6,012	+4,008%	+$9.83K	﹤0.01%	5925
2022 Q4	$254	Sell	150 -2	-1%	-$3	﹤0.01%	6551
2022 Q3	$0	Sell	152 -356	-70%	-$1.06K	﹤0.01%	7703
2022 Q2	$1K	Buy	508 +185	+57%	+$1.13K	﹤0.01%	6683
2022 Q1	$2K	Sell	323 -18,944	-98%	-$186K	﹤0.01%	6723
2021 Q4	$315K	Buy	+19,267	New	+$224K	﹤0.01%	5012

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo's PRDS Position: Q3 2023 in Review

Wells Fargo sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 151 shares — an estimated $273 sold.

Wells Fargo first reported a position in PRDS in Q4 2021 and held it in 7 quarters. The position peaked at $315K in Q4 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Wells Fargo reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 151 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $273.
Wells Fargo first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Wells Fargo's Pardes Biosciences, Inc. Common Stock position peaked at $315K in Q4 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.